目的 分析注射用己酮可可堿聯(lián)合奧扎格雷鈉治療急性腦梗死的臨床療效。方法 選取2015年3月—2020年10月北京市豐臺中西醫(yī)結(jié)合醫(yī)院收治的112例急性腦梗死患者，按隨機數(shù)字表法將患者分為對照組和治療組，每組各56例。對照組靜脈滴注注射用奧扎格雷鈉，80 mg/次，溶于500 mL生理鹽水中，2次/d。治療組在對照組治療基礎(chǔ)上靜脈滴注注射用己酮可可堿，0.2 g/次，溶于250 mL生理鹽水中，1次/d，輸注過程中患者平臥，2～3 h內(nèi)滴注完成。兩組療程均為14 d。觀察兩組的臨床療效，比較兩組治療前后美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、簡式Fugl-Meyer評定量表（FMA）評分、腦卒中專門化生存質(zhì)量量表（SS-QOL）評分及血小板壓積（PCT）、血小板聚集率（PAgT）、纖維蛋白原（FIB）和炎癥相關(guān)指標(biāo)[中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）、血小板與淋巴細(xì)胞比值（PLR）]的變化。結(jié)果 治療后，治療組總有效率是94.64%，顯著高于對照組的82.14%（P＜0.05）。治療3、7、14 d后，兩組NIHSS評分均較同組治療前顯著降低（P＜0.05）；治療后，治療組患者NIHSS評分顯著低于對照組（P＜0.05）。治療后，兩組FMA、SS-QOL評分均較治療前顯著增加（P＜0.05）；治療后，治療組FMA、SS-QOL評分高于對照組（P＜0.05）。治療后，兩組PCT、PAgT、FIB、NLR、PLR均顯著下降（P＜0.05）；治療后，治療組凝血及炎癥相關(guān)指標(biāo)顯著低于對照組（P＜0.05）。結(jié)論 注射用己酮可可堿聯(lián)合奧扎格雷鈉治療急性腦梗死的效果確切，能在較佳的安全性基礎(chǔ)上，有效促進(jìn)患者神經(jīng)功能、運動功能恢復(fù)，改善凝血功能紊亂和機體炎癥損害，利于患者生存狀態(tài)提升。

Objective To analyze the clinical efficacy of Ozagrel Sodium for injection combined with pentoxifylline in treatment of acute cerebral infarction. Methods A total of 112 patients with acute cerebral infarction admitted to Beijing Fengtai Hospital of Integrated Chinese and Western Medicine from March 2015 to October 2020 were selected and divided into control group and treatment group according to random number table method, with 56 cases in each group. Patients in the control group were iv administered with Ozagrel Sodium for injection, 80 mg/time, dissolved in 500 mL normal saline, twice daily. Patients in the treatment group were iv administered with Pentoxifylline for injection on the basis of the control group, 0.2 g/time, dissolved in 250 mL normal saline, once daily, the patient was supine during the infusion, and the infusion was completed within 2 to 3 h. The treatment course of both groups was 14 d. The clinical efficacy of the two groups was observed. After treatment, NIHSS score, FMA score, SS-QOL score, PCT, PAgT, FIB, NLR, and PLR in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 94.64%, which was significantly higher than that of the control group (82.14%, P < 0.05). After 3, 7 and 14 days of treatment, NIHSS scores in 2 groups were significantly lower than before treatment (P < 0.05). After treatment, the NIHSS score in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, FMA and SS-QOL scores in both groups were significantly increased compared with those before treatment (P < 0.05). After treatment, FMA and SS-QOL scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, PCT, PAgT, FIB, NLR, and PLR in two groups were significantly decreased (P < 0.05). After treatment, coagulation and inflammation related indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Ozagrel Sodium for injection combined with pentoxifylline has a definite effect in treatment of acute cerebral infarction, and can effectively promote the recovery of nerve function and motor function of patients, improve coagulation dysfunction and inflammation damage of the body, and improve the survival state of patients on the basis of better safety.

R971